Request the MTM White Paper

The full measure walkthrough, with intervention design and contract-level considerations. Or schedule a Stars strategy session with our Client Success team to review your contract's performance.

Request the White Paper Schedule a Session

Stars Navigator · Measure Reference

MTM Program Completion Rate for CMR

A Part D measure that reports the percentage of Medication Therapy Management (MTM) program enrollees who received a Comprehensive Medication Review (CMR) during the reporting period. It is on the CMS display page for MY2025 and MY2026 and returns as a new Star measure with the 2029 Star Ratings (MY2027).

Measure steward

PQA

Data source

Part D Plan Reporting (MTM)

Weighting category

Process

2027 status

Display page

Returns

2029 Star Ratings

Direction

Higher is better

Specification

Swipe to see all columns →

Element	Definition
Eligibility (CY2025 criteria)	Multiple chronic diseases from the 10 core chronic diseases, which now include HIV/AIDS; multiple Part D drugs; and an annual Part D cost threshold tied to the average cost of eight generic drugs. Members in a drug management program are also eligible. Enrollment is opt-out.
Denominator	MTM enrollees enrolled in the program for at least 60 days during the reporting period, plus enrollees with fewer than 60 days who received a CMR in that time.
Numerator	Enrollees who received at least one CMR during the reporting period.
CMR standard	An interactive, real-time, person-to-person review, in person or by telehealth, with the member or an authorized representative, followed by a written summary in the CMS Standardized Format.
Data validation	Contracts scoring below 95% on MTM data validation do not receive a rate.

The MY2027 specification will be published in the 2029 Star Ratings Technical Notes. Because the returning measure is treated as new, confirm denominator rules against that release.

From eligibility to a counted CMR

Step 1

Eligible

Meets the plan's targeting criteria under the 2025 rules.

Step 2

Enrolled

Opt-out enrollment places the member in the denominator once timing rules are met.

Step 3

Engaged

Member or authorized representative is reached and agrees to the review.

Step 4

Counted

CMR completed and written summary delivered in the Standardized Format.

Figure 1. The denominator is set at enrollment; only completed, documented CMRs reach the numerator.

Clinical and operational considerations

A CMR is a clinical encounter. It should reconcile medications across prescribers, assess each drug for indication, effectiveness, safety, and adherence, and produce a medication action list the member can use.
Authorized representatives count. Cognitive impairment is common in MTM-eligible populations, and a caregiver can complete the CMR on the member's behalf.
The 2025 eligibility expansion grew the denominator. Capacity planning for MY2027 should start from the expanded eligible population, not historical volumes.
Documentation is part of the measure. A review without a compliant written summary does not count, and data validation failures remove the rate entirely.
Cut points reset. As a new measure, there is no prior-year cut point and no guardrail limiting movement in its first year.
Language access affects reach. Outreach in the member's preferred language improves contact and completion in diverse populations.

Where performance is lost

Swipe to see all columns →

Driver	Effect on the measure
Contact rates	Calls from unrecognized numbers go unanswered; enrollees remain open
Member skepticism	Outreach is mistaken for sales or fraud
Scheduling	Reviews require dedicated time and frequent callbacks
Summary compliance	Incomplete or late written summaries invalidate completed reviews
Capacity	Expanded eligibility without matching pharmacist hours

Policy watch

Swipe to see all columns →

	Change
MY2025 and MY2026	Display page only, following the MTM eligibility changes effective in 2025.
2029 Star Ratings (MY2027)	Returns as a new Star measure. CMRs completed in 2027 count.
Measure set	Eleven administrative measures are removed across the 2028 and 2029 Star Ratings, so the returning measure enters a smaller set.
Litigation	Clover v. HHS (S.D. Ga., May 2026) named the MTM measure among those improperly included in Clover's 2026 rating. CMS has appealed to the 11th Circuit.

References

CMS. 2027 Star Ratings Measures and Weights.
CMS. Star Ratings Technical Notes, MTM Program Completion Rate for CMR.
CMS. Contract Year 2024 Policy and Technical Changes final rule (MTM eligibility criteria).
CMS. Contract Year 2027 Medicare Advantage and Part D Final Rule (CMS-4208-F3), April 2, 2026.
Clover Insurance Co. v. HHS (S.D. Ga., May 27, 2026); CMS memorandum on 2027 Quality Bonus Payment recalculation, June 17, 2026.

Specifications are summarized for education. Consult the PQA measure specifications and CMS Star Ratings Technical Notes for the measurement year in question. Prepared by the MedWatchers clinical pharmacy team, October 2026.